瑞格列奈联合α-葡萄糖苷酶抑制剂治疗老年T2DM患者的效果观察  

Effect observation of repaglinide combined withα-glucosidase inhibitor in the treatment of elderly T2DM patients

作　　者：吕秀娟[1] 陈新[1] 王艳[1] 逄琳 曹清红 LYU Xiu-juan;CHEN Xin;WANG Yan(Department of Geriatrics,Shenyang Fourth People's Hospital,Shenyang 110031,China)

机构地区：[1]沈阳市第四人民医院老年医学科,110031

出　　处：《中国现代药物应用》2023年第17期151-153,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察分析瑞格列奈联合α-葡萄糖苷酶抑制剂治疗老年2型糖尿病(T2DM)患者的效果。方法98例老年T2DM患者,以数字号形式随机分为对照组和观察组,每组49例。对照组患者行瑞格列奈治疗,观察组行瑞格列奈联合α-葡萄糖苷酶抑制剂治疗。比较两组患者临床疗效以及治疗前后的糖化血红蛋白、空腹血糖、餐后2 h血糖、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰高血糖素样肽-1(GLP-1)水平。结果观察组治疗总有效率93.88%高于对照组的75.51%,差异具有统计学意义(χ^(2)=6.376,P=0.012<0.05)。治疗后,观察组患者糖化血红蛋白(6.15±0.43)%、空腹血糖(5.86±0.70)mmol/L、餐后2 h血糖(7.11±0.32)mmol/L均低于对照组的(7.27±0.66)%、(7.14±0.94)mmol/L、(8.88±0.41)mmol/L,差异均具有统计学意义(P<0.05)。治疗后,观察组患者FINS(14.17±0.59)mU/L、GLP-1(5.07±0.26)pmol/L高于对照组的(9.97±0.93)mU/L、(3.14±0.24)pmol/L,HOMA-IR(3.31±0.53)低于对照组的(4.44±0.66),差异均具有统计学意义(P<0.05)。结论老年T2DM患者行瑞格列奈联合α-葡萄糖苷酶抑制剂治疗,疗效显著,可以有效控制患者血糖水平,胰岛素分泌情况改善,值得推广。Objective To observe and analyze the effect of repaglinide combined withα-glucosidase inhibitor in the treatment of elderly type 2 diabetes mellitus(T2DM)patients.Methods A total of 98 elderly T2DM patients were randomly divided into control group and observation group,with 49 cases in each group.The control group was treated with repaglinide,and the observation group was treated with repaglinide andα-glucosidase inhibitor.Both groups were compared in terms of clinical efficacy,glycated hemoglobin,fasting glucose,2 h postprandial glucose,fasting insulin(FINS),Homeostasis Model Assessment of Insulin Resistance(HOMA-IR),and glucagon-like peptide-1(GLP-1)levels before and after treatment.Results The total effective rate of 93.88%in the observation group was higher than that of 75.51%in the control group,and the difference was statistically significant(χ^(2)=6.376,P=0.012<0.05).After treatment,the observation group had glycated hemoglobin of(6.15±0.43)%,fasting blood glucose of(5.86±0.70)mmol/L,and 2 h postprandial glucose of(7.11±0.32)mmol/L,which were lower than those of(7.27±0.66)%,(7.14±0.94)mmol/L,and(8.88±0.41)mmol/L in the control group,and the differences were statistically significant(P<0.05).After treatment,FINS of(14.17±0.59)mU/L and GLP-1 of(5.07±0.26)pmol/L in the observation group were higher than those of(9.97±0.93)mU/L and(3.14±0.24)pmol/L in the control group;HOMA-IR of(3.31±0.53)in the observation group was lower than that of(4.44±0.66)in the control group;the differences were statistically significant(P<0.05).Conclusion In elderly T2DM patients,repaglinide combined withα-glucosidase inhibitor has significant therapeutic effect,which can effectively control the blood glucose level of patients and improve the insulin secretion,and is worth promoting.

关 键 词：老年2型糖尿病 Α-葡萄糖苷酶抑制剂 瑞格列奈 

分 类 号：R587.1[医药卫生—内分泌]